Items Tagged ‘tamoxifen’

April 28th, 2016

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen

By

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently published in the Journal of Clinical Oncology. The majority of breast cancers, referred to as hormone-positive breast cancers, […]

View full entry

Tags: aromasin, Breast Cancer, exemestane, HER2-negative, hormone-positive, News, premenopausal, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen


January 20th, 2016

Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer

By

Quality of life issues and different side effects caused by treatment may help determine which type of hormone therapy is most appropriate for postmenopausal women with ductal carcinoma in situ, particularly among women 60 years of age or older. These results were recently published in The Lancet. Hormone-positive breast cancers, which comprise approximately 75% of […]

View full entry

Tags: anastrozole, Arimidex, Breast Cancer, Carcinoma In Situ Breast cancer, DCIS, News, tamoxifen


October 28th, 2015

The Type of Breast Cancer Determines Effectiveness of Different Hormonal Therapies

By

According to the results of a recent study published in the Journal of Clinical Oncology, women with certain subtypes of hormone-positive breast cancer appear to benefit differently when treated with hormone therapy. Hormone-positive breast cancer refers to breast cancer that is stimulated to grow from the female hormone, estrogen. Therefore, a standard treatment component for […]

View full entry

Tags: AI, anti-estrogen agent, aromatase inhibitors, Breast Cancer, Femara, hormone-positive breast cancer, IDC, ILC, letrozole, News, tamoxifen


June 9th, 2015

Arimidex® More Effective than Tamoxifen in Prevention of Recurrence in Early Breast Cancer

By

For patients with a common type of breast cancer known as ductal carcinoma in situ (DCIS), the drug Arimidex® (anastrozole) may provide better protection against recurrence than tamoxifen. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical […]

View full entry

Tags: anastrozole, Arimidex, Breast Cancer, Carcinoma In Situ Breast cancer, DCIS, ductal carcinoma in situ, News, tamoxifen


December 19th, 2014

Study Confirms Role of Ovarian Suppression and Aromasin for Younger Women With Hormone-sensitive Breast Cancer

By

Ovarian suppression combined with the anti-estrogen drug Aromasin® (exemestane) appears to greatly reduce the risk of breast cancer recurrence in younger women according to the results of the Suppression of Ovarian Function Trial (SOFT) presented at the 2014 San Antonio Breast Cancer Symposium in Texas.[1] These results were also published online simultaneously in The New […]

View full entry

Tags: aromasin, Breast Cancer, News, ovarian suppression, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen


December 16th, 2014

IBIS-I Trial Confirms Greater Than Fifteen Year Benefit of Tamoxifen to Reduce Risk of Breast Cancer in High-Risk Women

By

Long term results of the International Breast Cancer Intervention Study-I (IBIS-I) were presented at the 2014 San Antonio Breast Cancer Symposium, confirming that tamoxifen significantly decreased the risk of developing breast cancer in high-risk women. The IBIS-1 clinical study was designed to investigate the long-term risks and benefits of taking tamoxifen to prevent breast cancer […]

View full entry

Tags: Breast Cancer, breast cancer prevention, cancer prevention, News, Screening/Prevention Breast Cancer, tamoxifen


August 19th, 2014

Aromasin is New Treatment Option for Young Women With Hormone-sensitive Breast Cancer

By

The results of a recently completed clinical study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and now published online in the New England Journal of Medicine demonstrate that Aromasin® (exemestane), is more effective than tamoxifen, in preventing breast cancer recurrence in young women who also receive post-surgical treatment […]

View full entry

Tags: aromasin, Breast Cancer, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen


May 29th, 2014

Updated Guidelines for Adjuvant Tamoxifen in Hormone-Positive Breast Cancer

By

The American Society of Clinical Oncology (ASCO) has updated their guidelines for the use of adjuvant endocrine therapy, particularly adjuvant tamoxifen (Nolvadex®), for women with hormone receptor-positive breast cancer. This update, which focuses on duration of treatment, was published early online in the Journal of Clinical Oncology. A majority of breast cancers are estrogen receptor-positive (ER-positive), […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen, treatment duration